David Moore, MD
Payments from drug & device makers
What this record shows
24 manufacturers reported payments, led by UCB SA at 31.1% of the total. Reporting peaked in 2019 at $3,082 and has fallen 82.9% since, to $528 in 2025.
Across 109 payments — averaging $46.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$2K
- Livanova USA, Inc.$1K
- AbbVie$579
- Bristol Myers Squibb$530
- SK Life Science, Inc.$110
- Biogen$106
- plus $830 from 18 others
Across 300 payments — averaging $3577.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$778K
- H. Lundbeck A S$157K
- Bristol Myers Squibb$72K
- SK Life Science, Inc.$20K
- GW Research Limited$17K
- GSK$17K
- plus $12K from 2 others
What the payments were for
- Travel & lodging$2,71253%
- Food & beverage$2,40247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 11 | $1,589 |
| Livanova USA, Inc. | 11 | $1,371 |
| AbbVie(2 entities) | 32 | $579 |
| Bristol Myers Squibb | 1 | $530 |
| SK Life Science, Inc. | 7 | $110 |
| Biogen | 5 | $106 |
| Eisai Inc. | 3 | $95 |
| Supernus Pharmaceuticals, Inc. | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Lilly USA, LLC | 4 | $63 |
| Neurelis, Inc. | 3 | $51 |
| Ceribell, Inc. | 1 | $50 |
| Greenwich Biosciences, Inc. | 2 | $50 |
| UCB, Inc. | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $45 |
| Medtronic | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Genentech USA, Inc. | 1 | $39 |
| EMD Serono, Inc. | 1 | $28 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Catalyst Pharmaceuticals, Inc. | 1 | $13 |
| Zogenix Inc. | 1 | $11 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,253
How this compares
$5,114 in reported general payments places this provider in the 80th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 24 | $353,851 |
| BanzelRufinamide | 32 | $136,638 |
| EpidiolexCannabidiol (Cbd) | 15 | $108,449 |
| Rufinamide | 120 | $98,856 |
| KeppraLevetiracetam | 26 | $60,927 |
| Lacosamide | 408 | $53,822 |
| FingolimodFingolimod Hcl | 19 | $53,319 |
| LamictalLamotrigine | 33 | $44,970 |
| AustedoDeutetrabenazine | 12 | $44,000 |
| FycompaPerampanel | 29 | $33,059 |
| Divalproex Sodium ErDivalproex Sodium | 242 | $23,637 |
| VimpatLacosamide | 23 | $21,746 |
| TopamaxTopiramate | 12 | $20,739 |
| XcopriCenobamate | 18 | $19,600 |
| Divalproex Sodium | 171 | $19,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Banzel, Fycompa | $95 | $169,69761 claims |
| UCB SAKeppra | $1,589 | $60,92726 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $68 | $44,00012 claims |
| UCB, Inc.Vimpat, Nayzilam | $49 | $39,61336 claims |
| SK Life Science, Inc.Xcopri | $110 | $19,60018 claims |
| Lundbeck LLCOnfi | $40 | $15,07611 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $65 | $14,42811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 neurology providers in Iowa.
Other neurology in Ames
- Anu BawejaAmes$6K
- Olesya GrinenkoAmes$3K
- Semira RamicAmes$1K
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.